Mallinckrodt’s Steven Romano elected NPC board chair

Print Friendly, PDF & Email

Dr. Steven Romano

WASHINGTON — The National Pharmaceutical Council (NPC) announced Thursday that Dr. Steven Romano, executive vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, has been elected chair of NPC’s board of directors for 2021-2022. Dr. Romano has served on NPC’s board as vice chair for the past year.

“Dr. Romano’s passion for discovering innovative medicines for patients, along with his experience in the current regulatory environment, make him particularly well suited to lead NPC’s Board,” said John O’Brien, president and chief executive officer. “As NPC moves ahead in its efforts to bring smart health policy research and analysis to pressing policy discussions, we look forward to having Dr. Romano play an important and guiding role in that process.”
Dr. Romano has been with Mallinckrodt since 2015 and is responsible for research and development, medical affairs, health economics and outcomes research, safety, pharmacovigilance and regulatory affairs functions. He is also a board-certified psychiatrist with more than 25 years of experience in the pharmaceutical industry.

Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, where he served in a series of senior roles, including senior vice president, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Before Pfizer, he spent four years at Eli Lilly performing clinical research. Dr. Romano received his bachelor’s degree in biology from Washington University in St. Louis and his medical degree from the University of Missouri-Columbia. He completed his residency and fellowship at New York Hospital-Cornell Medical Center, where he then served on the medical school faculty for six years.

“I am honored to be elected chairman of NPC’s board of directors,” Dr. Romano said. “Through its many research and education initiatives, NPC plays an incredibly important role in developing studies and collaborating with other stakeholders to bring data-driven health care policy solutions to the forefront. I look forward to working with my fellow Board members in the year ahead to further NPC’s mission.”

NPC’s board of directors also elected other members to its executive committee:

*   Christine Marsh, senior vice president, Market Access, Boehringer Ingelheim (vice chair)
*   Jennifer Norton, vice president, U.S. Value and Access, Amgen (treasurer)
*   Chris Leibman, senior vice president, Value, Access, Public Policy and Government Affairs, Biogen (member at-large)
*   Michael Ryan, senior vice president, Worldwide Value, Access, Policy and Health Economics and Outcomes Research, Bristol Myers Squibb (immediate past chair)

In addition to the executive committee, the board of directors made appointments to two standing board-level committees. Jan Hansen, vice president of the Evidence for Access Medical Unit, U.S. Medical Affairs, Genentech Inc., will continue to serve as chair of the research committee. Christian Nguyen, vice president, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, will be the chair of the Strategic Advisory Group.



Comments are closed.